-
CDK Verwandte Produkte (477)
Verwandte Produkte (477)
-
PROTAC CDK9 Degrader-1 (Standard)
0 ImagesArt. -Nr.: HY-103628RCAS. Nr.: 2118356-96-8
-
Amantadine hydrochloride (Standard)
0 ImagesSynonyms: 1-Adamantanamine hydrochloride (Standard); 1-Adamantylamine hydrochloride (Standard); 1-Aminoadamantane hydrochloride (Standard)Amantadine (hydrochloride) (Standard) is the analytical standard of Amantadine (hydrochloride). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.
-
Dinaciclib (Standard)
0 ImagesArt. -Nr.: HY-10492RCAS. Nr.: 779353-01-4Synonyms: SCH 727965 (Standard)Dinaciclib (Standard) is the analytical standard of Dinaciclib (HY-10492). This product is intended for research and analytical applications. Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
-
GSK3326595 (Standard)
0 ImagesSynonyms: EPZ015938 (Standard)GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563). This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma.
-
(-)-Enitociclib (Standard)
0 ImagesArt. -Nr.: HY-103019BRCAS. Nr.: 1610408-96-2Synonyms: (R)-Enitociclib (Standard); (-)-BAY-1251152 (Standard); (-)-VIP152 (Standard)(-)-Enitociclib (Standard) is the analytical standard of (-)-Enitociclib (HY-103019B). This product is intended for research and analytical applications. (-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies.
-
CDK modulator 1
0 ImagesArt. -Nr.: HY-W809647CAS. Nr.: 1203565-13-2
-
OM137
0 ImagesArt. -Nr.: HY-123279CAS. Nr.: 292170-13-9OM137 is an aurora kinase inhibitor, with an IC50 of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC50 of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes.
-
CDK9-IN-8 (Standard)
0 ImagesArt. -Nr.: HY-102039RCAS. Nr.: 2105956-51-0CDK9-IN-8 (Standard) is the analytical standard of CDK9-IN-8 (HY-102039). This product is intended for research and analytical applications. CDK9-IN-8 is a highly effective and selective CDK9 inhibitor with an IC50 of 12 nM.
-
Epmedin C (Standard)
0 ImagesArt. -Nr.: HY-N0260RCAS. Nr.: 110642-44-9Synonyms: Epimedin-C (Standard); Baohuoside-VI (Standard)Epmedin C (Standard) is the analytical standard of Epmedin C. This product is intended for research and analytical applications. Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia.
-
Daphnoretin (Standard)
0 ImagesDaphnoretin (Dephnoretin; Thymelol) (Standard) is the analytical standard of Daphnoretin (HY-N0699). This product is used for research and analytical applications. Daphnoretin is a protein kinase C (PKC) activator that can inhibit the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and has antiviral activity. Daphnoretin exerts its anti-tumor effect by inhibiting the activation of the PI3K/AKT signaling pathway, triggering the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and the activation of the NLRP3 inflammasome. Daphnoretin can regulate the differentiation and maturation of dendritic cells, by down-regulating the phosphorylation level of JNK, inhibiting its immune stimulating function, thereby playing a protective role in skin transplant rejection reactions.
-
Raddeanin A (Standard)
0 ImagesArt. -Nr.: HY-N0819RCAS. Nr.: 89412-79-3Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
-
NU6140 (Standard)
0 ImagesArt. -Nr.: HY-107419RCAS. Nr.: 444723-13-1NU6140 (Standard) is the analytical standard of NU6140 (HY-107419). This product is intended for research and analytical applications. NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.
-
BML-259 (Standard)
0 ImagesArt. -Nr.: HY-108348RCAS. Nr.: 267654-00-2
-
Olomoucine (Standard)
0 ImagesArt. -Nr.: HY-W011428RCAS. Nr.: 101622-51-9Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM). Olomoucine regulates cell cycle and shows anti-melanin tumor activity.
-
K00546 (Standard)
0 ImagesArt. -Nr.: HY-103647RCAS. Nr.: 443798-47-8K00546 (Standard) is the analytical standard of K00546 (HY-103647). This product is intended for research and analytical applications. K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively.
-
Palbociclib-d4
0 ImagesArt. -Nr.: HY-W654305CAS. Nr.: 1628752-63-5Synonyms: PD 0332991-d4Palbociclib-d4 is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
-
Protein kinase inhibitor 13
0 ImagesArt. -Nr.: HY-169670CAS. Nr.: 721964-45-0
-
Senexin B (Standard)
0 ImagesArt. -Nr.: HY-101800RCAS. Nr.: 1449228-40-3Synonyms: SNX2-1-165 (Standard); BCD-115 (Standard)Senexin B (Standard) (SNX2-1-165 (Standard)) is the analytical standard of Senexin B (HY-101800). This product is intended for research and analytical applications. Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
-
Trilaciclib hydrochloride (Standard)
0 ImagesSynonyms: G1T28 hydrochloride (Standard)
-
(R)-Simurosertib (Standard)
0 ImagesArt. -Nr.: HY-100888ARCAS. Nr.: 1330782-69-8(R)-Simurosertib (Standard) is the analytical standard of (R)-Simurosertib (HY-100888A). This product is intended for research and analytical applications. (R)-Simurosertib ((R)-TAK-931) is the (R)-enantiomer of Simurosertib. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM .
